Jiaoyang Cai, MD, PhD

photo of Jiaoyang Cai

Jiaoyang Cai’s passion and the sense of responsibility she feels for acute lymphoblastic leukemia (ALL) patients led her to pursue a career in multicenter clinical research. As a pediatrician for more than 10 years, she is dedicated to working for children with cancer and has never questioned her career path.

Dr. Cai earned her medical degree in 2007 from Shanghai Jiao Tong University School of Medicine in Shanghai, China. She also completed a PhD in 2013 from the same institution where she worked on the prognostic influence of minimal residual disease in childhood advanced neuroblastoma. In 2005 and 2006, she received the First Grade scholarship for postgraduates of Shanghai Jiao Tong University, School of Medicine and, in 2007, the Excellent Graduate of Shanghai recognition.

In 2015 and 2018, Dr. Cai participated in the Biostatistics training program at St. Jude Children’s Research Hospital.

Dr. Cai currently works in Shanghai Children’s Medical Center (SCMC) /National Children’s Medical Center–Shanghai (NCMCS) where she is an attending physician with expertise in pediatric oncology. She established the first long-term follow-up clinic for pediatric hematology/oncology patients in China in 2018, focusing on health status and quality of life after childhood cancer. In addition to her clinical duties, she also serves as the Director of the Big Data and Analytics Office at SCMC/NCMCS; this office currently hosts and maintains China’s Childhood Leukemia Registry, an assignment directly from China’s National Health Committee.

“Within the Master of Science in Global Child Health program, I can stay connected with top-of-class specialists in enhancing treatment and care of childhood cancers. After the training, I will be more competent in what I am doing for the China Childhood Leukemia Registration and Management System and the Chinese Children Cancer Group (CCCG)-ALL multicenter clinical study group. I believe this program will help me to continue my commitment to children with cancer and reach my future career goal of becoming a specialist of clinical studies.”

Hometown: Shanghai, China


MD – Shanghai Jiao Tong University, School of Medicine, Shanghai, China (2013)

PhD – Shanghai Jiao Tong University, School of Medicine, Shanghai, China (2017)


Yang W, Cai J, Shen S, et al. Pulse therapy with vincristine and dexamethasone in childhood acute lymphoblastic leukemia: a multicenter, open-label, randomized, phrase 3 non-inferiority study. Lancet Oncology. [In press]

Tang J, Yu J, Cai J, et al. Prognostic Factors for CNS Control in Children with Acute Lymphoblastic Leukemia Treated Without Cranial Irradiation [published online ahead of print]. Blood. blood.2020010438, 2021.

Cheung YT, Zhang H, Cai J, et al. Identifying Priorities for Harmonizing Guidelines for the Long-Term Surveillance of Childhood Cancer Survivors in the Chinese Children Cancer Group (CCCG). JCO Glob Oncol. 7:261-276, 2021.

Shen S, Chen X, Cai J, et al. Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. JAMA Oncol. 6(3):358-366, 2020.

Zhu Y, Yang R, Cai J, et al. Septicemia after chemotherapy for childhood acute lymphoblastic leukemia in China: A multicenter study CCCG-ALL-2015. Cancer Med. 9(6):2113-2121, 2020.

Cai J, Yu J, Zhu X, et al. Treatment abandonment in childhood acute lymphoblastic leukaemia in China: a retrospective cohort study of the Chinese Children's Cancer Group. Arch Dis Child. 104(6):522-529, 2019.

Cai J, Huang X, Yin M, et al. A novel fusion gene PLEKHA6-NTRK3 in langerhans cell histiocytosis. Int J Cancer. 144(1):117-124, 2019.

Shen S, Cai J, Chen J, et al. Long-term results of the risk-stratified treatment of childhood acute lymphoblastic leukemia in China. Hematol Oncol. 36(4):679-688, 2018.

Cai J, Pan C, Tang Y, et al. Multivariate analysis of risk factors for patients with stage 4 neuroblastoma who were older than 18 months at diagnosis: a report from a single institute in Shanghai, China. J Cancer Res Clin Oncol. 143(7):1327-1335, 2017.

Pan C, Cai JY, Xu M, et al. Renal tumor in developing countries: 142 cases from a single institution at Shanghai, China. World J Pediatr. 11(4):326-330, 2015.

Yin M, Cai J, Thorner PS. Congenital renal tumor: metanephric adenoma, nephrogenic rest, or malignancy?. Pediatr Dev Pathol. 18(3):245-250, 2015.

Cai J, Pan C, Lu Q, et al. Childhood renal tumor: a report from a Chinese Children's Cancer Group. Biomed Res Int. 2014:894341, 2014.

Cai JY, Pan C, Tang YJ, et al. Minimal residual disease is a prognostic marker for neuroblastoma with bone marrow infiltration. Am J Clin Oncol. 35(3):275-278, 2012.

Cai JY, Tang YJ, Jiang LM, Pan C, Chen J, Tang JY. Prognostic influence of minimal residual disease detected by flow cytometry and peripheral blood stem cell transplantation by CD34+ selection in childhood advanced neuroblastoma. Pediatr Blood Cancer. 49(7):952-957, 2007.